Liftaz 250mg/125mg Injection
Marketer
Emcure Pharmaceuticals Ltd
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Liftaz 250mg/125mg Injection
Combiflox 250mg/125mg Injection, a dual-action antibiotic, combats diverse bacterial infections by hindering microbial proliferation and propagation. Administration should strictly follow a healthcare provider's guidance. Complete the prescribed regimen, even with symptom improvement; premature cessation may compromise efficacy. Potential side effects include nausea, vomiting, diarrhea, and dyspepsia. Report worsening side effects immediately to your physician. Seek urgent medical attention for allergic reactions (skin rashes, itching, edema, respiratory distress). Inform your doctor about all concurrent medications, including those for pre-existing conditions. Pregnant or lactating individuals require prior medical consultation. Alcohol consumption should be avoided due to potential increased drowsiness. While typically non-impairing, refrain from driving if drowsiness or dizziness occurs. Adequate rest, balanced nutrition, and hydration are crucial for optimal recovery. Your doctor may order blood tests and other diagnostics to monitor treatment response.
Primary Ingredients of Liftaz 250mg/125mg Injection
No information provided. Please provide the text you wish me to rephrase.
Uses of Liftaz 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Liftaz 250mg/125mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
Common Side effects of Liftaz 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Liftaz 250mg/125mg Injection:
This medication will be administered by your physician or their qualified staff. Self-medication is strongly discouraged.
How Liftaz 250mg/125mg Injection works:
Ceftriaxone/Sulbactam 250mg/125mg Injection (Liftaz) combines the antibiotic Ceftriaxone with the beta-lactamase inhibitor Sulbactam. Ceftriaxone's mechanism involves disrupting bacterial cell wall synthesis, thereby hindering bacterial survival. Sulbactam's role is to counteract bacterial resistance mechanisms, optimizing Ceftriaxone's antibacterial efficacy.
SAFETY ADVICE
AlcoholSAFE
There are no known adverse reactions from co-administering Liftaz 250mg/125mg Injection and alcohol.
PregnancySAFE IF PRESCRIBED
Administration of Liftaz 250mg/125mg Injection is typically deemed safe for pregnant individuals. Preclinical trials in animals have indicated minimal or absent negative impacts on fetal development; nevertheless, data from human trials remain scarce.
Breast feedingCAUTION
Administering Liftaz 250mg/125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's treatment course and until the medication is fully cleared from her system.
DrivingUNSAFE
Administering Liftaz 250mg/125mg Injection can lead to reduced awareness, visual impairment, drowsiness, and dizziness. Driving is prohibited should these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data regarding the administration of Liftaz 250mg/125mg Injection to individuals with renal impairment is scarce. Seek medical advice from your physician.
LiverCAUTION
Administering Liftaz 250mg/125mg Injection to individuals with severe hepatic impairment requires careful consideration and potential dosage modification. Patients with mild to moderate liver disease do not typically require Liftaz 250mg/125mg Injection dose adjustments. Physician consultation is advised.
What if you forget to take Liftaz 250mg/125mg Injection :
Omitting a scheduled dose of Liftaz 250mg/125mg Injection necessitates contacting your physician.
Facts to Know About Liftaz 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Anti-Infectives |
3,018 People bought this recently